NMD Pharma begins first clinical trial

NMD Pharma is pleased to announce that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, a small molecule inhibitor of skeletal muscle specific ClC-1 ion channels, into clinical trials as a novel treatment for the symptoms of myasthenia gravis.

Read more here:

Globenewswire

Medwatch

Previous
Previous

NMD Pharma Initiates Combined Phase I/II Clinical trial

Next
Next

Welcome to Monique Schiersing and Roel Bulthuis as new BoD members